ATE472555T1 - Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential - Google Patents

Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential

Info

Publication number
ATE472555T1
ATE472555T1 AT02762548T AT02762548T ATE472555T1 AT E472555 T1 ATE472555 T1 AT E472555T1 AT 02762548 T AT02762548 T AT 02762548T AT 02762548 T AT02762548 T AT 02762548T AT E472555 T1 ATE472555 T1 AT E472555T1
Authority
AT
Austria
Prior art keywords
screening
alpha
molecules
peptide fragments
calcium channels
Prior art date
Application number
AT02762548T
Other languages
English (en)
Inventor
Jean-Marc Sabatier
Waard Michel De
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE472555T1 publication Critical patent/ATE472555T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
AT02762548T 2001-07-27 2002-07-26 Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential ATE472555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110117A FR2827867B1 (fr) 2001-07-27 2001-07-27 Utilisation de fragments peptidiques de la sous-unite alpha-1 des canaux calciques, comportant le cas echeant des mutations, pour le criblage de molecules d'interet therapeutique
PCT/FR2002/002679 WO2003011906A2 (fr) 2001-07-27 2002-07-26 UTILISATION DE FRAGMENTS PEPTIDIQUES DE LA SOUS-UNITE α-1 DES CANAUX CALCIQUES, COMPORTANT LE CAS ECHEANT DES MUTATIONS, POUR LE CRIBLAGE DE MOLECULES D'INTERET THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
ATE472555T1 true ATE472555T1 (de) 2010-07-15

Family

ID=8866024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762548T ATE472555T1 (de) 2001-07-27 2002-07-26 Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential

Country Status (8)

Country Link
US (1) US20050089938A1 (de)
EP (1) EP1412386B1 (de)
JP (1) JP2005508310A (de)
AT (1) ATE472555T1 (de)
CA (1) CA2455398A1 (de)
DE (1) DE60236871D1 (de)
FR (1) FR2827867B1 (de)
WO (1) WO2003011906A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849041B1 (fr) * 2002-12-23 2005-03-04 Commissariat Energie Atomique Proteine chimerique pour le criblage d'agonistes et d'antagonistes des voies de signalisation cellulaires dependantes des recepteurs couples aux proteines g
WO2013113060A1 (en) * 2012-01-31 2013-08-08 The University Of Western Australia Peptide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits

Also Published As

Publication number Publication date
DE60236871D1 (de) 2010-08-12
WO2003011906A3 (fr) 2003-10-02
FR2827867A1 (fr) 2003-01-31
EP1412386A2 (de) 2004-04-28
US20050089938A1 (en) 2005-04-28
CA2455398A1 (fr) 2003-02-13
EP1412386B1 (de) 2010-06-30
JP2005508310A (ja) 2005-03-31
WO2003011906A2 (fr) 2003-02-13
FR2827867B1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
MXPA03010144A (es) Proteinas de agutinacion al peptido beta-amiloide y polinucleotidos que las codifican.
DE60233147D1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
EP1440981A3 (de) Vollständige humane cDNS
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
WO2003038063A3 (en) Human secreted proteins
NO962188D0 (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
EP1442295A4 (de) Diagnostische tests auf periostinbasis
DE60236921D1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
DK1390543T3 (da) Nye polynukleotider og polypeptider af IFNalfa-17-genet
DE69328549D1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DE60233555D1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
ATE472555T1 (de) Verwendung von peptidfragmenten aus der alpha-1 untereinheit von kalziumkanälen, die mutationen enthalten können, für das screening von molekülen mit therapeutischem potential
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
ATE313551T1 (de) Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung
WO2002070668A3 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
DE69918446D1 (de) Polynucleotide and polypeptide basb033 aus neisseria meningitidis und ihre verwendungen
BRPI0415355A (pt) triarilimidazóis
DK1078064T3 (da) Forbindelser fra moraxella catarrhalis
ATE284960T1 (de) Nukleotid sequenzen kodierend für das lysr3 gen
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
DE60040668D1 (de) Antibakterielles protein chlamysin-b, dafür kodierendes gen und ein expresionssystem dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties